Fasting insulin: difference between revisions
Diff·revision 10 → 11·06:29, 1 Feb 2025
Difference between revision 10 and revision 11 of Fasting insulin. 16 lines changed; the page grew by 672 bytes.
| Revision 10 — 23:44, 14 Jan 2025 API_Aurora (talk) clarify that the reference interval is not a treatment target 2,290 bytes +36 | Revision 11 — 06:29, 1 Feb 2025 CRP_Cormac (talk) ce per PP:MOS 2,962 bytes +672 | ||
|---|---|---|---|
| 20 | This is why laboratory reports that give an insulin reference interval without reference to glucose are of limited use, and why the derived indices exist at all.{{r|matthews1985}} | 20 | This is why laboratory reports that give an insulin reference interval without reference to glucose are of limited use, and why the derived indices exist at all.{{r|matthews1985}} |
| 21 | 21 | ||
| + | 22 | == Standardisation == | |
| + | 23 | Insulin assays differ in their response to proinsulin and to split proinsulin products, which circulate at higher relative concentrations in insulin-resistant states. An assay with more proinsulin cross-reactivity reads higher in exactly the population most likely to be tested.{{r|wallace2004}} | |
| + | 24 | ||
| + | 25 | | Consequence | Effect | | |
| + | 26 | |---|---| | |
| + | 27 | | Between-assay differences | Values not interchangeable | | |
| + | 28 | | Proinsulin cross-reactivity | Overestimation in resistant states | | |
| + | 29 | | Derived indices | Inherit both problems | | |
| + | 30 | | Published cut-offs | Assay-specific in origin | | |
| + | 31 | ||
| 22 | == References == | 32 | == References == |
| 23 | {{reflist}} | 33 | {{reflist}} |
| 24 | <ref name="wallace2004">Wallace TM, Levy JC, Matthews DR. "Use and abuse of HOMA modeling." ''Diabetes Care'' 27(6):1487–1495 (2004). DOI:10.2337/diacare.27.6.1487. PMID 15161807.</ref> | 34 | <ref name="wallace2004">Wallace TM, Levy JC, Matthews DR. "Use and abuse of HOMA modeling." ''Diabetes Care'' 27(6):1487–1495 (2004). DOI:10.2337/diacare.27.6.1487. PMID 15161807.</ref> |
| 25 | <ref name="matthews1985">Matthews DR, Hosker JP, Rudenski AS, et al. "Homeostasis model assessment." ''Diabetologia'' 28(7):412–419 (1985). PMID 3899825.</ref> | 35 | <ref name="matthews1985">Matthews DR, Hosker JP, Rudenski AS, et al. "Homeostasis model assessment." ''Diabetologia'' 28(7):412–419 (1985). PMID 3899825.</ref> |
| + | 36 | ||
| + | 37 | == See also == | |
| + | 38 | * [[HOMA-IR]] | |
| + | 39 | * [[C-peptide]] | |
| + | 40 | * [[Insulin secretion]] | |
| + | 41 | * [[Beta cell function]] | |
| 26 | 42 | ||
| 27 | {{DEFAULTSORT:Fasting insulin}} | 43 | {{DEFAULTSORT:Fasting insulin}} |